At the Cancer Vaccine Institute (CVI) at UW Medicine, we are excited to reveal a polished, new look that represents our ongoing commitment to creating a world where cancer is managed, treated, and ultimately prevented by vaccines. This rebrand — which includes a redesigned logo, updated visual identity, and refined messaging — reflects both our Husky Pride and the evolution of our work, as we start anticipating the first FDA-approved cancer vaccine within the next decade.
What You Can Look Forward To
Communicating our story and the impact of our work is important for us to be able to recruit patients for our studies, recruit talent for our team, and interest donors to support our work. We have refreshed our CVI branding and website to align with that of UW Medicine. The updated website makes it easier for our patients to find information on open clinical trials, better understand the clinical trials process, and hear about other patients' experiences. The updates also make it easier for doctors who refer patients to us to understand how our clinical trials process works and how to integrate it into their patients’ care. The website also more explicitly shares the need and impact of philanthropy and simplifies the gift-making process.
The New Logo: A Symbol of Progress
Our revamped logo now lives in the UW Medicine signature colors, with the Husky Purple symbolizing passion, power, and strength and the Husky Gold speaking to the institution’s standard of excellence and positive impact. We retained the central element of our original mark, which represents the biological interaction key to how our cancer vaccines work in the body: the binding of an antigen-presenting cell (APC) with a T cell.
Our former and current brand marks
When we administer a cancer vaccine, it contains either DNA, RNA, or protein components called antigens. Antigens are carefully selected molecular flags, derived from cancer cells, designed to help the immune system recognize tumors. These antigens — represented by the purple particle at the center of our logo — are captured by APCs circulating in the body. APCs then present the antigen to the immune system, particularly white blood cells (T cells). This interaction helps prime the immune system to know what cancer cells look like and thus effectively recognize and eliminate them.
Our technology is based on our research of the past two decades, and we are excited to tell its story through the new logo. We also see it as a symbol of the growth and bond of the CVI community — our scientists, doctors, nurses, patients, and philanthropists — illustrated by the two purple arms linking together, surrounding our golden core of transformative care.
What’s Next?
The rebrand is only the beginning. As we move forward with new studies, clinical trials, and collaborations, our reimagined identity will help us communicate more effectively with patients, partners, and the scientific community. We will continue to share updates and stories on our blog, social media channels (LinkedIn, Facebook, BlueSky, and soon Instagram), and newsletters (subscribe to our newsletter).
Thank You for Your Support
To everyone who has supported us along the way — thank you. Your belief in our mission and generous gifts fuels our breakthroughs in cancer research and therapies. We invite you to explore our new website and join us in our mission to ignite the immune system to end cancer.
